By Associate Professor Behzad Hajarizadeh

Conference Abstracts

Lamoury FM; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty GA; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, NETHERLANDS, Amsterdam, Vol. 66, pp. S710 - S710, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, NETHERLANDS, Amsterdam, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31901-3

Kwon AJ; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Estes C; Razavi H; Gray RT, 2017, 'O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued', in Journal of Virus Eradication, Elsevier BV, Vol. 3, pp. 5 - 5, http://dx.doi.org/10.1016/s2055-6640(20)30895-5

Reports

Wilkinson A; Griffin S; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Broady T; Combo T, 2024, Australia’s progress towards hepatitis C elimination: Annual Report 2024, http://dx.doi.org/10.26190/unsworks/30597

Carson J; Hajarizadeh B; Dore G, 2024, Monitoring hepatitis C treatment uptake in Australia: Issue #14, July 2024, Kirby Institute, UNSW, Sydney, 14, http://dx.doi.org/10.26190/unsworks/30340, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-14-july-2024

Wilkinson A; Griffin S; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Aitken C; Broady T; Combo T, 2023, Australia’s progress towards hepatitis C elimination: Annual Report 2023, http://dx.doi.org/10.26190/4d4f-5n41

Hajarizadeh B; Carson J; Dore G, 2023, Monitoring hepatitis C treatment uptake in Australia: Issue #13, July 2023, The Kirby Institute, UNSW, Sydney, Australia, http://dx.doi.org/10.26190/81wp-fr56, https://www.kirby.unsw.edu.au/research/reports/monitoring-hepatitis-c-treatment-uptake-australia-issue-13-july-2023

Wilkinson A; Hayes M; Hellard M; Stoové M; Dore G; Grebely J; Pedrana A; Doyle J; Thompson A; Hajarizadeh B; Alavi M; Aitken C; Broady T; Combo T, 2022, Australia's progress towards hepatitis C elimination: annual report 2022, http://dx.doi.org/10.26190/ge22-aq55

Wilkinson A; Hellard M; Pedrana A; Alavi M; Stoove M; Doyle J; Aitken C; Dore G; Thompson A; Broady T; Grebely J; Hajarizadeh B, 2020, Australia’s progress towards hepatitis C elimination: annual report 2020, Burnet Institute and Kirby Institute, http://dx.doi.org/10.26190/unsworks/28056, https://kirby.unsw.edu.au/report/australias-progress-towards-hepatitis-c-elimination-annual-report-2020

Wilkinson A; Hellard M; Pedrana A; Alavi M; Stoove M; Doyle J; Aitken C; Dore G; Thompson A; Grebely J; Hajarizadeh B, 2019, Australia’s progress towards hepatitis C elimination: annual report 2019, Burnet Institute and Kirby Institute, http://dx.doi.org/10.26190/unsworks/28055, https://kirby.unsw.edu.au/report/australias-progress-towards-hepatitis-c-elimination-annual-report-2019

Kwon J; Gray R; Dore G; Grebely J; Guy R; Hajarizadeh B; Cunningham E, 2017, 2017 Estimates and Projections of the Hepatitis C Virus Epidemic in NSW: Summary Report, Sydney: Kirby Institute, UNSW Sydney

Preprints

Joseph Yeoh YK; Dore GJ; Lockart I; Danta M; Flynn C; Blackmore C; Levy MT; George J; Alavi M; Hajarizadeh B, 2023, Temporal change in etiology and clinical characteristics of hepatocellular carcinoma in a large cohort of patients with hepatocellular carcinoma in New South Wales, Australia, http://dx.doi.org/10.1101/2023.02.20.23286164

Kwon J; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT, Australia on Track to Achieve Who HCV Elimination Targets Following Rapid Initial DAA Treatment Uptake: A Modelling Study, http://dx.doi.org/10.2139/ssrn.3213670

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916

Lockhart I; Yeo MGH; Hajarizadeh B; Dore GJ; Danta M, Hepatocellular Carcinoma Incidence After Hepatitis C Cure Among Patients With Advanced Fibrosis or Cirrhosis: A Systematic Review and Meta-Analysis, http://dx.doi.org/10.2139/ssrn.3950271

Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ; Group S-CS, Reduced Hepatitis C Incidence Associated with Rapid Treatment Scale-Up in Australian Prisons: Treatment-as-Prevention in the SToP-C Study, http://dx.doi.org/10.2139/ssrn.3709824

Other

Hajarizadeh B, 2017, Generic direct acting antiviral treatment: The first step towards elimination of hepatitis C in Iran, http://dx.doi.org/10.5812/hepatmon.45788

Back to profile page